Genetic study of Quebec residents finds air pollution trumps ancestry

March 20, 2018

Air pollution leaves its mark on the human body, a newly published Canadian study, led by Philip Awadalla of the Ontario Institute for Cancer Research in Toronto, has found. For example, the results show that someone who was born in Saguenay but who grew up in Montreal will develop a genetic expression signature along with associated risk factors that more closely resemble those of a native Montrealer. These results may help develop better predictors of disease risk.

Read More

Lawson researchers receive $4.4 million to study personalized medicine at LHSC 

March 19, 2018

With $4.4M in new funding, Dr. Richard Kim and team at Lawson Health Research Institue (LHSC) will follow patient outcomes and assess the cost-effectiveness of LHSC’s personalized medicine program, providing evidence on the relationship between the cost of the program and how patient care is improved. This program focuses on pharmacogenomics, the study of genetic changes that alter the way a person responds to individual drugs.

Read More

Canada SynBio 2018

March 15, 2018

On March 6 Ontario Genomics, in partnership with ISED Canada and the Genome Canada Enterprise, hosted Canada’s first national conference focused on Engineering Biology. Over 275 people attended the packed MaRS Discovery District auditorium for the event with speakers and attendees from academia, industry and government across Canada, the US and globally. The day was about learning, mobilizing the community, creating opportunities for collaboration and partnership, and ultimately to start charting a course for Canada to capitalize on this emerging area.

Read More

Genomics enters its teen years

February 22, 2018

Andre Picard, commenting on the recent report on Canada’s Personal Genome Project, suggests that genomics has entered its frustrating adolescent phase. This study found that our genome “is a lot more messy and unpredictable than anyone could have imagined. Like a typical teenager.”

Read More

Why mapping your DNA may be less reliable than you think

February 21, 2018

Scientists leading Canada’s Personal Genome Project say they have taken the deepest dive possible into human DNA, conducting the most thorough analysis that current computing allows on the whole genome sequences of 56 Canadians. Their investigation shows how much we still have to learn.

Read More

Nicoya Lifesciences raises $2 million to change how the next generation of drugs will be discovered

February 20, 2018

Ontario Genomics is delighted with the recent news that Nicoya Lifesciences (Nicoya) has raised $2 million in financing from a syndicate of investors in the Toronto-Waterloo corridor, led by Ripple Ventures. Ontario Genomics, through its Pre-commercialization Business Development Fund, previously invested in Nicoya to help advance Nicoya’s flagship product, OpenSPR – a label-free, real time molecule sensor. It has many applications, including enabling drug discovery. Congratulations to the team at Nicoya!

Read More

Canadian Genomics Cloud launched

February 16, 2018

A national consortium of industry and academic collaborators have launched the Canadian Genomics Cloud, an integrated software platform to manage, analyze and share genome sequence and clinical data. As detailed in an accompanying white paper, this public cloud computing platform will give every scientist in the country unfettered access to award-winning technology empowering precision medicine and other applications in genomics research.

Read More

Canada’s Genomics Enterprise launches “CanSeq150” to lay the foundation for Canada’s next 150 years of science

February 14, 2018

To commemorate the 150th Birthday of Canada in 2017 and to lay the foundation of Canadian excellence in research for the next 150 years, Canada’s Genomics Enterprise (CGEn) and its partners are embarking upon the Canada 150 Sequencing Project (CanSeq150). The aim is to sequence 150 new genomes to support sequence-based genomics research in Canada by enabling future…

Read More

Fabry disease precision treatment one step closer to Canadian patients

February 7, 2018

Fabry disease is a rare genetic disease caused by a deficiency in the enzyme alpha-galactosidase A (a-Gal A) that causes a buildup of a specific type of fat in the body. Galafold™ (migalastat), a new oral drug to treat some patients with Fabry disease, has just received a positive recommendation by the CADTH Common Drug Review for reimbursement and listing with provincial drug formularies.

Read More